Transducer of regulated creb-binding proteins (TORCs) transcription and function is impaired in Huntington's disease

Human Molecular Genetics

Volumn 21, Issue 15, 2012, Pages 3474-3488

  Chaturvedi, Rajnish Kumar ^a,b   Hennessey, Thomas ^a,c   Johri, Ashu ^a   Tiwari, Shashi Kant ^b   Mishra, Divya ^b   Agarwal, Swati ^a   Kim, Yoon Seong ^a,d   Flint Beal, M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; BETA ACTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GLUTAMINE; HUNTINGTIN; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN CYTC; PROTEIN TORC1; PROTEIN TORC2; PROTEIN TORC3; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NRF1; TRANSDUCER OF REGULATED CREB BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CELL; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

MUS MUSCULUS;

EID: 84864506840     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds178     Document Type: Article

References (62)

1. Browne, S.E. and Beal, M.F. (2004) The energetics of Huntington's disease. Neurochem. Res., 29, 531-546.
2. Milakovic, T. and Johnson, G.V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem., 280, 30773-30782.
3. Oliveira, J.M., Jekabsons, M.B., Chen, S., Lin, A., Rego, A.C., Goncalves, J., Ellerby, L.M. and Nicholls, D.G. (2007) Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem., 101, 241-249.
4. Chaturvedi, R.K. and Beal, M.F. (2008) Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci., 1147, 395-412.
5. Mochel, F. and Haller, R.G. (2011) Energy deficit in Huntington disease: why it matters. J. Clin. Invest., 121, 493-499.
6. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J. and Lesort, M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet., 13, 1407-1420.
7. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
8. Orr, A.L., Li, S., Wang, C.E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P.G., Greenamyre, J.T. and Li, X.J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci., 28, 2783-2792.
9. Trushina, E., Dyer, R.B., Badger, J.D. 2nd, Ure, D., Eide, L., Tran, D.D., Vrieze, B.T., Legendre-Guillemin, V., McPherson, P.S., Mandavilli, B.S. et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol., 24, 8195-8209.
10. Chang, D.T., Rintoul, G.L., Pandipati, S. and Reynolds, I.J. (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis., 22, 388-400.
11. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
12. Cha, J.H. (2007) Transcriptional signatures in Huntington's disease. Prog. Neurobiol., 83, 228-248.
13. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
14. Nucifora, F.C. Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
15. Chen-Plotkin, A.S., Sadri-Vakili, G., Yohrling, G.J., Braveman, M.W., Benn, C.L., Glajch, K.E., DiRocco, D.P., Farrell, L.A., Krainc, D., Gines, S. et al. (2006) Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol. Dis., 22, 233-241.
16. Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238-2243.
17. Cong, S.Y., Pepers, B.A., Evert, B.O., Rubinsztein, D.C., Roos, R.A., van Ommen, G.J. and Dorsman, J.C. (2005) Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol. Cell. Neurosci., 30, 12-23.
18. Sugars, K.L., Brown, R., Cook, L.J., Swartz, J. and Rubinsztein, D.C. (2004) Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem., 279, 4988-4999.
19. Chaturvedi, R.K., Adhihetty, P., Shukla, S., Hennessy, T., Calingasan, N., Beal, M.F., Yang, L., Starkov, A., Kiaei, M., Cannella, M. et al. (2009) Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet., 18, 3048-3065.
20. Chaturvedi, R.K., Calingasan, N.Y., Yang, L., Hennessey, T., Johri, A. and Beal, M.F. (2010) Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet., 19, 3190-3205.
21. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
22. Lin, J., Handschin, C. and Spiegelman, B.M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab., 1, 361-370.
23. Chaturvedi, R.K. and Beal, M.F. (2008) PPAR: a therapeutic target in Parkinson's disease. J. Neurochem., 106, 506-518.
24. Weydt, P., Pineda, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., Strand, A.D. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab., 4, 349-362.
25. McGill, J.K. and Beal, M.F. (2006) PGC-1alpha, a new therapeutic target in Huntington's disease? Cell, 127, 465-468.
26. Kim, J., Moody, J.P., Edgerly, C.K., Bordiuk, O.L., Cormier, K., Smith, K., Beal, M.F. and Ferrante, R.J. (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet., 19, 3919-3935.
27. Conkright, M.D., Canettieri, G., Screaton, R., Guzman, E., Miraglia, L., Hogenesch, J.B. and Montminy, M. (2003) TORCs: transducers of regulated CREB activity. Mol. Cell, 12, 413-423.
28. Wu, Z., Huang, X., Feng, Y., Handschin, C., Feng, Y., Gullicksen, P.S., Bare, O., Labow, M., Spiegelman, B. and Stevenson, S.C. (2006) Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. Proc. Natl Acad. Sci. USA, 103, 14379-14384.
29. Li, S., Zhang, C., Takemori, H., Zhou, Y. and Xiong, Z.Q. (2009) TORC1 regulates activity-dependent CREB-target gene transcription and dendritic growth of developing cortical neurons. J. Neurosci., 29, 2334-2343.
30. Wang, B., Goode, J., Best, J., Meltzer, J., Schilman, P.E., Chen, J., Garza, D., Thomas, J.B. and Montminy, M. (2008) The insulin-regulated CREB coactivator TORC promotes stress resistance in Drosophila. Cell Metab., 7, 434-444.
31. Hietakangas, V. and Cohen, S.M. (2008) TORCing up metabolic control in the brain. Cell Metab., 7, 357-358.
32. Sasaki, T., Takemori, H., Yagita, Y., Terasaki, Y., Uebi, T., Horike, N., Takagi, H., Susumu, T., Teraoka, H., Kusano, K. et al. (2011) SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron, 69, 106-119.
33. Mantamadiotis, T., Lemberger, T., Bleckmann, S.C., Kern, H., Kretz, O., Martin Villalba, A., Tronche, F., Kellendonk, C., Gau, D., Kapfhammer, J. et al. (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet., 31, 47-54.
34. Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, S., Vianna, C.R., Reznick, R.M. et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 119, 121-135.
35. Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C. et al. (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol., 3, e101.
36. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
37. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H., Persichetti, F., Cattaneo, E. and MacDonald, M.E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-2809.
38. Schilling, G., Savonenko, A.V., Klevytska, A., Morton, J.L., Tucker, S.M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H.H. et al. (2004) Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice. Hum. Mol. Genet., 13, 1599-1610.
39. Wheeler, V.C., Gutekunst, C.A., Vrbanac, V., Lebel, L.A., Schilling, G., Hersch, S., Friedlander, R.M., Gusella, J.F., Vonsattel, J.P., Borchelt, D.R. et al. (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet., 11, 633-640.
40. Kovacs, K.A., Steullet, P., Steinmann, M., Do, K.Q., Magistretti, P.J., Halfon, O. and Cardinaux, J.R. (2007) TORC1 is a calcium- and cAMP-sensitive coincidence detector involved in hippocampal long-term synaptic plasticity. Proc. Natl Acad. Sci. USA, 104, 4700-4705.
41. Mayr, B.M., Canettieri, G. and Montminy, M.R. (2001) Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Proc. Natl Acad. Sci. USA, 98, 10936-10941.
42. Larsson, N.G., Wang, J., Wilhelmsson, H., Oldfors, A., Rustin, P., Lewandoski, M., Barsh, G.S. and Clayton, D.A. (1998) Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet., 18, 231-236.
43. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C. et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98, 115-124.
44. Kelly, D.P. and Scarpulla, R.C. (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev., 18, 357-368.
45. D'Aurelio, M., Vives-Bauza, C., Davidson, M.M. and Manfredi, G. (2010) Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells. Hum. Mol. Genet., 19, 374-386.
46. Gines, S., Seong, I.S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J.F., Wheeler, V.C., Persichetti, F. and MacDonald, M.E. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet., 12, 497-508.
47. Choi, Y.S., Lee, B., Cho, H.Y., Reyes, I.B., Pu, X.A., Saido, T.C., Hoyt, K.R. and Obrietan, K. (2009) CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease. Neurobiol. Dis., 36, 259-268.
48. Klevytska, A.M., Tebbenkamp, A.T., Savonenko, A.V. and Borchelt, D.R. (2010) Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease. J. Neuropathol. Exp. Neurol., 69, 396-404.
49. Zhou, Y., Wu, H., Li, S., Chen, Q., Cheng, X.W., Zheng, J., Takemori, H. and Xiong, Z.Q. (2006) Requirement of TORC1 for late-phase long-term potentiation in the hippocampus. PLoS One, 1, e16.
50. Giampa, C., Middei, S., Patassini, S., Borreca, A., Marullo, F., Laurenti, D., Bernardi, G., Ammassari-Teule, M. and Fusco, F.R. (2009) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci., 29, 902-910.
51. DeMarch, Z., Giampa, C., Patassini, S., Bernardi, G. and Fusco, F.R. (2008) Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 30, 375-387.
52. Giampa, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F.S. and Fusco, F.R. (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One, 5, e13417.
53. Jiang, H., Nucifora, F.C. Jr, Ross, C.A. and DeFranco, D.B. (2003) Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet., 12, 1-12.
54. Jiang, H., Poirier, M.A., Liang, Y., Pei, Z., Weiskittel, C.E., Smith, W.W., DeFranco, D.B. and Ross, C.A. (2006) Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis., 23, 543-551.
55. Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P. et al. (2001) CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature, 413, 179-183.
56. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397-408.
57. Koo, S.H., Flechner, L., Qi, L., Zhang, X., Screaton, R.A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P. et al. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature, 437, 1109-1111.
58. Canettieri, G., Koo, S.H., Berdeaux, R., Heredia, J., Hedrick, S., Zhang, X. and Montminy, M. (2005) Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab., 2, 331-338.
59. Siu, Y.T., Ching, Y.P. and Jin, D.Y. (2008) Activation of TORC1 transcriptional coactivator through MEKK1-induced phosphorylation. Mol. Biol. Cell, 19, 4750-4761.
60. Sasaki, T., Takemori, H., Yagita, Y., Terasaki, Y., Uebi, T., Horike, N., Takagi, H., Susumu, T., Teraoka, H., Kusano, K. et al. (2011) SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron, 69, 106-119.
61. Jeong, H., Cohen, D.E., Cui, L., Supinski, A., Savas, J.N., Mazzulli, J.R., Yates, J.R. 3rd, Bordone, L., Guarente, L. and Krainc, D. (2011) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med., 18, 159-165.
62. Liu, L., Zhang, X., Wang, L., Yang, R., Cui, L., Li, M., Du, W. and Wang, S. (2010) The neuroprotective effects of Tanshinone IIA are associated with induced nuclear translocation of TORC1 and upregulated expression of TORC1, pCREB and BDNF in the acute stage of ischemic stroke. Brain Res. Bull., 82, 228-233.